Literature DB >> 17687414

Rationale for recommendations for lipid testing and reporting by Australian pathology laboratories.

David R Sullivan1, David W Thomas, David P Tognarini.   

Abstract

Entities:  

Year:  2007        PMID： 17687414      PMCID： PMC1904425     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN： 0159-8090


× No keyword cloud information.
  14 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome.

Authors:  Nader Rifai
Journal:  Clin Chem       Date:  2005-03       Impact factor: 8.327

3.  National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.

Authors:  Andrew Tonkin; Philip Barter; James Best; Andrew Boyden; John Furler; Ken Hossack; David Sullivan; Peter Thompson; Margarite Vale; Catherine Cooper; Malia Robinson; Eleanor Clune
Journal:  Heart Lung Circ       Date:  2005-12       Impact factor: 2.975

4.  Web-based assessment of cardiovascular disease risk in routine primary care practice in New Zealand: the first 18,000 patients (PREDICT CVD-1).

Authors:  Lot Bannink; Susan Wells; Joanna Broad; Tania Riddell; Rod Jackson
Journal:  N Z Med J       Date:  2006-11-17

5.  The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study.

Authors:  Peter M Brindle; Alex McConnachie; Mark N Upton; Carole L Hart; George Davey Smith; Graham C M Watt
Journal:  Br J Gen Pract       Date:  2005-11       Impact factor: 5.386

6.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

7.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983

8.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

9.  A strategy to reduce cardiovascular disease by more than 80%.

Authors:  N J Wald; M R Law
Journal:  BMJ       Date:  2003-06-28

10.  Recommendations for lipid testing and reporting by Australian pathology laboratories.

Authors:  Charles A Appleton; Grahame Caldwell; Alan McNeil; Matthew Meerkin; Ken Sikaris; David R Sullivan; David W Thomas; David P Tognarini
Journal:  Clin Biochem Rev       Date:  2007-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.